Alvotech is trading 4.13% down at ISK 604 after a strong recent rally, with no fresh negative company-specific announcement identified to explain the August 26, 2026 decline.
- Recent gains followed the Lotus Pharmaceutical licensing agreement, FDA inspection progress and first-half results.
- Those catalysts were announced before August 26, while broader biotech sentiment remained positive.
- The move is best classified as an unexplained pullback, not a confirmed company-driven reversal.